Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.omtn.2016.12.003 http://scihub22266oqcxt.onion/10.1016/j.omtn.2016.12.003 C5363494!5363494!28325278     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Ther+Nucleic+Acids 2017 ; 6 (ä): 116-32 Nephropedia Template TP {{tp|p=28325278|t=2017. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics |pdf=|usr=}}{{28325278}} gab.com Text Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics JO: Mol Ther Nucleic Acids http://www.kidney.de/pget.php?&tw=1&pmid=28325278 #FOAvip A main challenge in realizing the full potential of nucleic acid therapeutics is efficient delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with asialoglycoprotein receptor (ASGPR). By conjugating it directly to the oligonucleotides or decorating it to a certain delivery system as a targeting moiety, GalNAc has achieved compelling successes in the development of nucleic acid therapeutics in recent years. Several oligonucleotide modalities are undergoing pivotal clinical studies, followed by a blooming pipeline in the preclinical stage. This review covers the progress of GalNAc-decorated oligonucleotide drugs, including siRNAs, anti-miRs, and ASOs, which provides a panorama for this field. Twit Text FOAVip Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics ????Mol Ther Nucleic Acids http://www.kidney.de/pget.php?&tw=1&pmid=28325278 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28325278 #FOAvip English Wikipedia <ref>{{Cite pmid|28325278}}</ref> Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics #MMPMID28325278 Huang Y Mol Ther Nucleic Acids 2017[Mar]; 6 (ä): 116-32 PMID28325278show ga A main challenge in realizing the full potential of nucleic acid therapeutics is efficient delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with asialoglycoprotein receptor (ASGPR). By conjugating it directly to the oligonucleotides or decorating it to a certain delivery system as a targeting moiety, GalNAc has achieved compelling successes in the development of nucleic acid therapeutics in recent years. Several oligonucleotide modalities are undergoing pivotal clinical studies, followed by a blooming pipeline in the preclinical stage. This review covers the progress of GalNAc-decorated oligonucleotide drugs, including siRNAs, anti-miRs, and ASOs, which provides a panorama for this field. äPreclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid The(epmc).pdf DeepDyve Pubget Overpricing